Medicine & Life Sciences
Safety-net Providers
100%
Drug Therapy
54%
Bevacizumab
49%
Breast Neoplasms
43%
rasburicase
38%
Jehovah's Witnesses
34%
Induction Chemotherapy
31%
Colonic Neoplasms
30%
Kinesin
28%
Triple Negative Breast Neoplasms
26%
Hispanic Americans
26%
gemcitabine
26%
Chemoradiotherapy
23%
Colorectal Neoplasms
23%
Platinum
23%
Rectal Neoplasms
22%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21%
Acute Myeloid Leukemia
21%
Meals
19%
Hypertension
19%
Albumins
18%
Lymphoma
18%
Costs and Cost Analysis
18%
Weight Loss
18%
Income
18%
Intercellular Signaling Peptides and Proteins
17%
Neutrophils
17%
Blood Platelets
17%
Outpatients
16%
Hospitalization
16%
Therapeutics
15%
Radiotherapy
15%
Phosphorylation
15%
Mutation
14%
Monoclonal Antibodies
13%
Blood Transfusion
13%
Recurrence
13%
Cytotoxins
13%
Survival
12%
romiplostim
12%
Darbepoetin alfa
11%
B-Lymphocytes
11%
Incidence
10%
Philadelphia Chromosome
9%
Fluorouracil
8%
Leucovorin
8%
Progression-Free Survival
8%
Platinum Compounds
8%
Quality Improvement
7%
Residual Neoplasm
7%
Social Sciences
costs
24%
hospitalization
24%
medication
15%
savings
13%
act
13%
time
7%
physician
6%
hospital system
6%
methodology
6%
laboratory testing
6%
drug
5%
electronics
5%
Medical records
5%